Identification

Name
Framycetin
Accession Number
DB00452  (APRD00618)
Type
Small Molecule
Groups
Approved
Description

A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed)

Structure
Thumb
Synonyms
  • Fradiomycin B
  • Framicetina
  • Framycetin
  • Framycétine
  • Framycetinum
  • Neomycin B
External IDs
ANTIBIOTIQUE EF 185
Product Ingredients
IngredientUNIICASInChI Key
Framycetin sulfateY3720KZ4TQ4146-30-9KWBUARAINLGYMG-JGMIRXPNSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sofra Tulle 10 X 10cmDressing1 %TopicalRoussel Canada Inc.1966-12-311996-09-09Canada
Sofra Tulle Strip (10 X 30cm)Dressing1 %TopicalRoussel Canada Inc.1974-12-311997-08-05Canada
Sofra-tulle Dressing 1%Dressing1 %TopicalErfa Canada 2012 Inc1994-12-31Not applicableCanada
Sofra-tulle Strip 1%Dressing1 %TopicalErfa Canada 2012 Inc1995-12-31Not applicableCanada
Soframycin Eye Drops 0.5%Solution / drops5 mgOphthalmicErfa Canada 2012 Inc2001-08-03Not applicableCanada
Soframycin Eye Drops 0.5%Solution / drops5 mgOphthalmicHoechst Roussel Canada Inc.1995-12-312000-07-28Canada
Soframycin Eye Drops 5mg/mlSolution / drops5 mgOphthalmicRoussel Canada Inc.1966-12-311997-08-05Canada
Soframycin Eye Ont 0.5%Ointment5 mgOphthalmicRoussel Canada Inc.1966-12-311997-08-05Canada
Soframycin Sterile Eye Ointment 0.5%Ointment5 mgOphthalmicErfa Canada 2012 Inc2001-08-03Not applicableCanada
Soframycin Sterile Eye Ointment 0.5%Ointment5 mgOphthalmicHoechst Roussel Canada Inc.1995-12-312000-07-28Canada
International/Other Brands
Isofra (Bouchara) / Izofra (Bouchara) / Leukase N (Dermapharm) / Pola (Royal) / Sofra-Tulle (sanofi-aventis) / Soframycin (sanofi-aventis) / Soframycine (Melisana)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Proctol OintmentFramycetin sulfate (1 %) + Dibucaine hydrochloride (0.5 %) + Esculin (1 %) + Hydrocortisone (0.5 %)OintmentRectalOdan Laboratories Ltd2003-08-06Not applicableCanada
Proctol SuppositoriesFramycetin sulfate (1 %) + Dibucaine hydrochloride (0.5 %) + Esculin (1 %) + Hydrocortisone (0.5 %)SuppositoryRectalOdan Laboratories Ltd2004-03-15Not applicableCanada
Proctosedyl OintmentFramycetin sulfate (10 mg) + Dibucaine hydrochloride (5 mg) + Esculin (10 mg) + Hydrocortisone (5 mg)OintmentRectalHoechst Roussel Canada Inc.1971-12-312006-07-28Canada
Proctosedyl OintmentFramycetin sulfate (10 mg) + Dibucaine hydrochloride (5 mg) + Esculin (10 mg) + Hydrocortisone (5 mg)OintmentRectalRoussel Canada Inc.1959-12-311997-08-05Canada
Proctosedyl OintmentFramycetin sulfate (1 %) + Dibucaine hydrochloride (0.5 %) + Esculin (1 %) + Hydrocortisone (0.5 %)OintmentRectalAptalis Pharma Canada Ulc2003-04-01Not applicableCanada
Proctosedyl SupFramycetin sulfate (10 mg) + Dibucaine hydrochloride (5 mg) + Esculin (10 mg) + Hydrocortisone (5 mg)SuppositoryRectalRoussel Canada Inc.1959-12-311996-09-09Canada
Proctosedyl SuppositoriesFramycetin sulfate (10 mg) + Dibucaine hydrochloride (5 mg) + Esculin (10 mg) + Hydrocortisone (5 mg)SuppositoryRectalHoechst Roussel Canada Inc.1959-12-311999-08-11Canada
Proctosedyl SuppositoriesFramycetin sulfate (1 %) + Dibucaine hydrochloride (0.5 %) + Esculin (1 %) + Hydrocortisone (0.5 %)SuppositoryRectalAptalis Pharma Canada Ulc1997-01-23Not applicableCanada
Ratio-proctosoneFramycetin sulfate (1 %) + Dibucaine hydrochloride (0.5 %) + Esculin (1 %) + Hydrocortisone (0.5 %)OintmentRectalTeva1997-02-03Not applicableCanada
Ratio-proctosoneFramycetin sulfate (1 %) + Dibucaine hydrochloride (0.5 %) + Esculin (1 %) + Hydrocortisone (0.5 %)SuppositoryRectalTeva1996-12-30Not applicableCanada
Categories
UNII
4BOC774388
CAS number
119-04-0
Weight
Average: 614.6437
Monoisotopic: 614.312285588
Chemical Formula
C23H46N6O13
InChI Key
PGBHMTALBVVCIT-VCIWKGPPSA-N
InChI
InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
IUPAC Name
(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(2R,3S,4R,5S)-5-{[(1R,2R,3S,5R,6S)-3,5-diamino-2-{[(2R,3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diol
SMILES

Pharmacology

Indication

For the treatment of bacterial blepharitis, bacterial bonjunctivitis, corneal injuries, corneal ulcers and meibomianitis. For the prophylaxis of ocular infections following foreign body removal

Structured Indications
Pharmacodynamics

Framycetin is used for the treatment of bacterial eye infections such as conjunctivitis. Framycetin is an antibiotic. It is not active against fungi, viruses and most kinds of anaerobic bacteria. Framycetin works by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Framycetin is useful primarily in infections involving aerobic bacteria bacteria.

Mechanism of action

Framycetin binds to specific 30S-subunit proteins and 16S rRNA, four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.

TargetActionsOrganism
A16S rRNA
inhibitor
Enteric bacteria and other eubacteria
A30S ribosomal protein S12
inhibitor
Escherichia coli (strain K12)
UC-X-C chemokine receptor type 4
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategory
Neomycin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Framycetin.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Framycetin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumFramycetin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidFramycetin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Framycetin can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmoxicillinThe serum concentration of Framycetin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Framycetin.Approved, Investigational
AmpicillinThe serum concentration of Framycetin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
ApocyninApocynin may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Framycetin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumFramycetin may increase the respiratory depressant activities of Atracurium.Experimental, Investigational
Atracurium besylateFramycetin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Framycetin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Framycetin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Framycetin can be decreased when it is combined with Bacampicillin.Approved, Investigational
BalsalazideBalsalazide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Framycetin.Investigational
BendazacBendazac may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Framycetin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzydamineBenzydamine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
BenzylpenicillinThe serum concentration of Framycetin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Framycetin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevoniumBevonium may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
Botulinum Toxin Type AFramycetin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BFramycetin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
BumadizoneBumadizone may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Framycetin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Framycetin.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental, Investigational
CarbenicillinThe serum concentration of Framycetin can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Framycetin can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarboplatinFramycetin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Framycetin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
CisatracuriumFramycetin may increase the respiratory depressant activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateFramycetin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Framycetin.Approved
Clodronic AcidFramycetin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Framycetin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateFramycetin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Framycetin can be decreased when it is combined with Cyclacillin.Approved
CyclosporineFramycetin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Framycetin.Experimental
D-LimoneneD-Limonene may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
DecamethoniumFramycetin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Framycetin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Framycetin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Framycetin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Framycetin.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Framycetin.Approved
Domoic AcidFramycetin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideFramycetin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
EpicillinThe serum concentration of Framycetin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Framycetin.Approved
EtanerceptEtanercept may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
Etidronic acidFramycetin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
EtoricoxibEtoricoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
exisulindexisulind may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Framycetin can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FlunixinFlunixin may decrease the excretion rate of Framycetin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Framycetin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Framycetin.Approved, Vet Approved
GallamineFramycetin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideFramycetin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Framycetin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
HigenamineHigenamine may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
IbandronateFramycetin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Framycetin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Framycetin.Experimental
LeflunomideLeflunomide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Framycetin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
MecamylamineFramycetin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational, Withdrawn
MetampicillinThe serum concentration of Framycetin can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of Framycetin can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Framycetin.Experimental
MetocurineFramycetin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideFramycetin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Framycetin can be decreased when it is combined with Mezlocillin.Approved, Investigational
MivacuriumFramycetin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Framycetin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinFramycetin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Framycetin.Experimental, Investigational
OlopatadineOlopatadine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Framycetin which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Framycetin.Approved
OxacillinThe serum concentration of Framycetin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Withdrawn
PamidronateFramycetin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumFramycetin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
PenamecillinThe serum concentration of Framycetin can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of Framycetin can be decreased when it is combined with Penimepicycline.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Framycetin.Experimental
PhenoxymethylpenicillinThe serum concentration of Framycetin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Framycetin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
PipecuroniumFramycetin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Framycetin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Framycetin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
PiroxicamPiroxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Framycetin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Framycetin can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental, Investigational
Procaine benzylpenicillinThe serum concentration of Framycetin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
PropicillinThe serum concentration of Framycetin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Framycetin.Experimental
PTC299PTC299 may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
PyrantelFramycetin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumFramycetin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Experimental, Investigational
RisedronateFramycetin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumFramycetin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
SuccinylcholineFramycetin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Framycetin can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of Framycetin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Framycetin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Framycetin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
TazobactamThe serum concentration of Framycetin can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronateFramycetin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateFramycetin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Framycetin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Framycetin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Framycetin can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
Tiludronic acidFramycetin may increase the hypocalcemic activities of Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Framycetin.Approved
TranilastTranilast may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Framycetin which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational
TubocurarineFramycetin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Framycetin.Approved
VecuroniumFramycetin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational
ZileutonZileuton may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidFramycetin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Framycetin which could result in a higher serum level.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Vanangamudi Subramaniam Sulur, Madhavan Srinivasan, Neelakandan Narayanan Chulliel, Haridas Sankar, Kuppusamy Senthilkumar, "Medicinal Cream Made Using Framycetin Sulphate and Chitosan and a Process to Make the Same." U.S. Patent US20120101056, issued April 26, 2012.

US20120101056
General References
Not Available
External Links
Human Metabolome Database
HMDB15129
KEGG Compound
C01737
PubChem Compound
8378
PubChem Substance
46508892
ChemSpider
8075
BindingDB
19
ChEBI
7508
ChEMBL
CHEMBL184618
Therapeutic Targets Database
DNC001005
PharmGKB
PA164743181
HET
NMY
Wikipedia
Framycetin
ATC Codes
R01AX08 — FramycetinD09AA01 — FramycetinS01AA07 — Framycetin
AHFS Codes
  • 52:04.04 — Antibacterials
  • 84:04.04 — Antibiotics
PDB Entries
1ei2 / 1i9v / 2a04 / 2b0q / 2et4 / 2fcy / 3c7r / 4lf6 / 4lfb / 4v52
show 7 more

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
OintmentRectal
SuppositoryRectal
SolutionAuricular (otic); Ophthalmic
DressingTopical1 %
OintmentAuricular (otic); Ophthalmic
Solution / dropsAuricular (otic); Ophthalmic
Solution / dropsTopical
OintmentTopical
Solution / dropsOphthalmic5 mg
OintmentOphthalmic5 mg
SprayNasal
Prices
Unit descriptionCostUnit
Neomycin Sulfate 500 mg tablet1.39USD tablet
Neomycin 500 mg tablet1.25USD tablet
Neomycin sulfate powder0.84USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP-7.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility64.7 mg/mLALOGPS
logP-2.8ALOGPS
logP-8.4ChemAxon
logS-0.98ALOGPS
pKa (Strongest Acidic)12.29ChemAxon
pKa (Strongest Basic)9.97ChemAxon
Physiological Charge6ChemAxon
Hydrogen Acceptor Count19ChemAxon
Hydrogen Donor Count13ChemAxon
Polar Surface Area353.11 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity135.9 m3·mol-1ChemAxon
Polarizability60.87 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 4,5-disubstituted 2-deoxystreptamines. These are 2-deoxystreptamine aminoglycosides that a glycosidically linked to a pyranose of furanose unit at the C4- and C5-positions.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
4,5-disubstituted 2-deoxystreptamines
Alternative Parents
O-glycosyl compounds / Disaccharides / Aminocyclitols and derivatives / Cyclohexylamines / Cyclohexanols / Oxanes / Tetrahydrofurans / 1,2-aminoalcohols / Oxacyclic compounds / Acetals
show 4 more
Substituents
4,5-disubstituted 2-deoxystreptamine / Disaccharide / Glycosyl compound / O-glycosyl compound / Aminocyclitol or derivatives / Cyclohexanol / Cyclohexylamine / Cyclitol or derivatives / Oxane / Tetrahydrofuran
show 16 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
aminoglycoside (CHEBI:7508) / 2-Deoxystreptamines (C01737)

Targets

1. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Chao PW, Chow CS: Monitoring aminoglycoside-induced conformational changes in 16S rRNA through acrylamide quenching. Bioorg Med Chem. 2007 Jun 1;15(11):3825-31. Epub 2007 Mar 13. [PubMed:17399988]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Trna binding
Specific Function
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Lo...
Gene Name
rpsL
Uniprot ID
P0A7S3
Uniprot Name
30S ribosomal protein S12
Molecular Weight
13736.995 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Famulok M, Huttenhofer A: In vitro selection analysis of neomycin binding RNAs with a mutagenized pool of variants of the 16S rRNA decoding region. Biochemistry. 1996 Apr 9;35(14):4265-70. [PubMed:8605174]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation. Acts as a receptor for extracellular ubiq...
Gene Name
CXCR4
Uniprot ID
P61073
Uniprot Name
C-X-C chemokine receptor type 4
Molecular Weight
39745.055 Da
References
  1. Litovchick A, Lapidot A, Eisenstein M, Kalinkovich A, Borkow G: Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities. Biochemistry. 2001 Dec 25;40(51):15612-23. [PubMed:11747436]
  2. Borkow G, Vijayabaskar V, Lara HH, Kalinkovich A, Lapidot A: Structure-activity relationship of neomycin, paromomycin, and neamine-arginine conjugates, targeting HIV-1 gp120-CXCR4 binding step. Antiviral Res. 2003 Nov;60(3):181-92. [PubMed:14638394]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34